Arbutus Biopharma
ABUS
ABUS
51 hedge funds and large institutions have $173M invested in Arbutus Biopharma in 2017 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 21 increasing their positions, 13 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
51
Holders Change
-2
Holders Change %
-3.77%
% of All Funds
1.16%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
11
Increased
21
Reduced
13
Closed
13
Calls
$149K
Puts
$5K
Net Calls
+$144K
Net Calls Change
+$172K
Top Buyers
| 1 |
1
BlackRock
New York
|
$3.79M |
| 2 |
2
Hudson Bay Capital Management
Stamford,
Connecticut
|
$2.02M |
| 3 |
3
Renaissance Technologies
New York
|
$2.03M |
| 4 |
OAM
4
Oxford Asset Management
Oxford,
United Kingdom
|
$1.74M |
| 5 |
5
Morgan Stanley
New York
|
$3.17M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
51
Point72 Asset Management
Stamford,
Connecticut
| – | -$1.39M | -224,655 | Closed |
|
|
CS
52
Credit Suisse
Zurich,
Switzerland
| – | -$1.09M | -176,091 | Closed |
|
|
SSA
53
Schonfeld Strategic Advisors
New York
| – | -$775K | -125,000 | Closed |
|
54
Vanguard Group
Malvern,
Pennsylvania
| – | -$488K | -78,634 | Closed |
|
55
Group One Trading
Chicago,
Illinois
| – | -$123K | -19,830 | Closed |
|
56
Fidelity Investments
Boston,
Massachusetts
| – | -$119K | -19,200 | Closed |
|
57
Jane Street
New York
| – | -$68K | -10,983 | Closed |
|
|
TRCT
58
Tower Research Capital (TRC)
New York
| – | -$51K | -8,283 | Closed |
|
|
PCM
59
Prelude Capital Management
New York
| – | -$21K | -3,400 | Closed |
|
|
CSS
60
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$2K | -300 | Closed |
|
|
NFG
61
Next Financial Group
Houston,
Texas
| – | -$1K | -200 | Closed |
|
|
AG
62
Advisor Group
Phoenix,
Arizona
| – | -$1K | -200 | Closed |
|